Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Company Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$5.00 to C$8.29
• 52-Week Range: N/A
• Volume: 1,232 shs
• Average Volume: 1,137 shs
• Market Capitalization: C$25.37 million
• P/E Ratio: N/A
• Dividend Yield: 2.79%
• Price Target: N/A
• Consensus Rating: N/A

AEZS Stock Analysis - Frequently Asked Questions

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Meta Platforms (META), Novavax (NVAX), Verizon Communications (VZ), Western Uranium & Vanadium (WUC), Air Canada (AC), Affirm (AFRM) and AutoZone (AZO).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:AEZS
• CUSIP: N/A
• CIK: N/A
• Web: www.aezsinc.com
• Phone: 18439003223
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-18,050,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.71%
• Return on Assets: -29.96%

Debt

• Debt-to-Equity Ratio: 1.80
• Current Ratio: 5.94
• Quick Ratio: 9.37

Sales & Book Value

• Annual Sales: C$2.37 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.46
• Book Value: C$10.68 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,060,000
• Free Float: N/A
• Market Cap: C$25.37 million
• Optionable: Not Optionable
• Beta: 2.26